adriamycinol has been researched along with cyclosporine in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bartlett, NL; Brophy, NA; Ehsan, MN; Fisher, GA; Halsey, J; Lum, BL; Sikic, BI | 1 |
| Guo, B; Heibein, AD; Maclean, DA; Parissenti, AM; Sprowl, JA | 1 |
| Dubbelboer, IR; Lennernäs, H; Lilienberg, E; Sjögren, E | 1 |
1 trial(s) available for adriamycinol and cyclosporine
| Article | Year |
|---|---|
Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance.
Topics: Adult; Aged; Cyclosporine; Doxorubicin; Drug Administration Schedule; Drug Resistance; Female; Humans; Male; Middle Aged; Neoplasms; Treatment Outcome | 1994 |
2 other study(ies) available for adriamycinol and cyclosporine
| Article | Year |
|---|---|
Role of aldo-keto reductases and other doxorubicin pharmacokinetic genes in doxorubicin resistance, DNA binding, and subcellular localization.
Topics: 20-Hydroxysteroid Dehydrogenases; 3-Hydroxysteroid Dehydrogenases; Aldehyde Reductase; Aldo-Keto Reductase Family 1 Member C3; Aldo-Keto Reductases; Breast Neoplasms; Cell Nucleus; Cholic Acids; Cyclosporine; DNA, Neoplasm; Doxorubicin; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Hydroxyprostaglandin Dehydrogenases; Intracellular Space; MCF-7 Cells; Oligonucleotide Array Sequence Analysis | 2012 |
Lipiodol does not affect the tissue distribution of intravenous doxorubicin infusion in pigs.
Topics: Animals; Cyclosporine; Doxorubicin; Ethiodized Oil; Excipients; Infusions, Intravenous; Intestinal Mucosa; Kidney; Liver; Myocardium; Swine | 2017 |